Affinage

NR1D1

Nuclear receptor subfamily 1 group D member 1 · UniProt P20393

Length
614 aa
Mass
66.8 kDa
Annotated
2026-06-10
100 papers in source corpus 53 papers cited in narrative 53 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 8/8 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

NR1D1 (REV-ERBα) is a heme-liganded nuclear receptor that operates as a potent transcriptional repressor at the interface of the circadian clock and tissue metabolism (PMID:18218725, PMID:22460952, PMID:26044300). Heme binds directly to its ligand-binding domain and gates recruitment of the NCoR-HDAC3 corepressor complex to target promoters (PMID:18218725, PMID:20414452). Two mechanistically distinct modes of action govern its genomic output: at the clock, REV-ERBα directly competes with ROR factors at RORE/RevDR2 motifs to repress BMAL1 and other positive-limb genes, while at metabolic genes it is tethered by lineage-determining transcription factors such as HNF6 to impose tissue-specific repression of lipid, glucose, bile acid, and drug-metabolism programs (PMID:26044300, PMID:27445394, PMID:29237721, PMID:30639375, PMID:30639455). NR1D1 and the paralogous REV-ERBβ share the great majority of genomic binding sites and act redundantly; their combined loss abolishes cell-autonomous rhythms and produces hepatic steatosis with derepression of clock and metabolic genes (PMID:22460952, PMID:22474260). Mechanistically, REV-ERBα-NCoR-HDAC3 deacetylates enhancer histones and evicts BRD4 and MED1 to oppose enhancer-promoter chromatin looping, providing the molecular basis for rhythmic transcriptional repression (PMID:29439026). REV-ERBα protein abundance is tightly controlled by degradation: CDK1 phosphorylation primes FBXW7-mediated ubiquitination, Siah2 drives circadian turnover, and inflammatory SUMOylation/ubiquitination triggers rapid loss during immune challenge (PMID:26392558, PMID:27238018, PMID:29533925). Beyond core clock and metabolic transcription, NR1D1 directly represses inflammasome components (NLRP3, IL-1β) and NF-κB signaling to restrain inflammation across colitis, microglial, and disc-degeneration models (PMID:30315268, PMID:30792350, PMID:38689641), suppresses RORγt-dependent Th17 cytokines (PMID:30590045), binds PARP1 to inhibit PARylation and DNA double-strand break repair (PMID:28249904, PMID:28599788), regulates microglial lipid-droplet metabolism and tau phagocytosis (PMID:37626048), and maintains skeletal-muscle SR calcium homeostasis by repressing myoregulin (PMID:35917173). Its activity is further integrated with cellular state through polyamine-driven translational control and mTORC1 signaling (PMID:33525630, PMID:33285244).

Mechanistic history

Synthesis pass · year-by-year structured walk · 16 steps
  1. 1990 High

    Established that human NR1D1/Rev-ErbAα, arising from opposite-strand transcription of the c-erbAα locus, is an orphan-like receptor that does not bind thyroid hormone, framing it as a distinct receptor whose ligand and function were unknown.

    Evidence cDNA cloning, Northern analysis, and thyroid hormone ligand-binding assay

    PMID:1971514

    Open questions at the time
    • No endogenous ligand identified
    • No transcriptional target or mechanism defined
  2. 1999 Medium

    Demonstrated NR1D1 acts as a sequence-specific repressor that antagonizes PPARα/RXRα at a defined response element, giving early evidence of direct DNA-binding repressor activity over metabolic genes.

    Evidence In vitro binding and transient transfection reporter assays on the HD-PPRE

    PMID:10428876

    Open questions at the time
    • In vitro only, single study
    • Corepressor machinery not yet defined
  3. 2008 High

    Identified heme as the endogenous ligand binding the LBD and controlling NCoR corepressor recruitment, resolving the long-standing question of how REV-ERBα repressor activity is regulated.

    Evidence Direct LBD ligand-binding biochemistry plus corepressor recruitment assay for REV-ERBα/β

    PMID:18218725

    Open questions at the time
    • Physiological heme dynamics not addressed
    • Full corepressor complex composition not defined here
  4. 2010 High

    Synthesized the model that heme-liganded REV-ERBα recruits NCoR-HDAC3 to repress BMAL1, positioning it as the negative limb of the core clock.

    Evidence Review integrating ligand-binding, corepressor recruitment, and gene expression data

    PMID:20414452

    Open questions at the time
    • Genome-wide binding not yet mapped
    • Redundancy with REV-ERBβ unresolved
  5. 2012 High

    Showed REV-ERBα and REV-ERBβ are largely redundant integral clock components: they share most genomic sites, overlap BMAL1 cistromes near metabolic genes, and their combined loss causes arrhythmia and hepatic steatosis, establishing clock-metabolism coupling.

    Evidence ChIP-seq cistromes, double-knockout mice/MEFs, behavioural and lipid metabolic profiling

    PMID:22460952 PMID:22474260

    Open questions at the time
    • Mode of metabolic gene targeting (direct vs tethered) unresolved
    • Tissue specificity of metabolic effects not dissected
  6. 2015 High

    Resolved how one receptor achieves both universal clock control and tissue-specific metabolic control by defining two modes: ROR competition at cognate sites versus HDAC3 recruitment at lineage-TF-tethered sites.

    Evidence ChIP-seq, domain mutagenesis, HDAC3 recruitment and liver TF tethering analysis

    PMID:26044300

    Open questions at the time
    • Identity of all tethering factors incomplete
    • Extent of tethering across tissues unresolved
  7. 2016 High

    Identified the degradation circuits controlling REV-ERBα abundance — Siah2-mediated circadian turnover and a CDK1-phosphorylation/FBXW7-ubiquitination axis — explaining how repressor amplitude and period are set post-translationally.

    Evidence E3-ligase screen, siRNA/overexpression, phosphorylation and ubiquitination assays, hepatic FBXW7 KO mice

    PMID:26392558 PMID:27238018

    Open questions at the time
    • Crosstalk between Siah2 and FBXW7 pathways unclear
    • Upstream signals triggering CDK1 phosphorylation in vivo not fully defined
  8. 2016 High

    Confirmed lineage-TF tethering in liver by showing HNF6 recruits Rev-erbα to shared lipid-gene promoters, with HNF6 loss abolishing Rev-erbα binding and derepressing lipogenesis.

    Evidence Liver-specific HNF6 KO with ChIP-seq and expression profiling

    PMID:27445394

    Open questions at the time
    • Whether tethering is required outside liver lipid genes unresolved
  9. 2018 High

    Defined the chromatin-level mechanism of repression: REV-ERBα-NCoR-HDAC3 deacetylates enhancers and evicts BRD4/MED1 to oppose enhancer-promoter looping, explaining rhythmic transcriptional output.

    Evidence Chromatin interaction analysis, ChIP-seq, corepressor Co-IP, BRD4/MED1 eviction assays

    PMID:29439026

    Open questions at the time
    • Generality of looping control beyond tested loci not established
  10. 2018 High

    Extended REV-ERBα function into immunity, showing direct repression of Nlrp3 and indirect repression via NF-κB p65, with genetic epistasis linking it to inflammasome and Th17 control.

    Evidence ChIP, reporter assays, Rev-erbα/Nlrp3 KO mice, colitis/EAE models, RORE competition assays

    PMID:30315268 PMID:30590045

    Open questions at the time
    • Relative contribution of direct vs NF-κB-mediated repression not quantified
    • Cell-type specificity of anti-inflammatory effect not fully mapped
  11. 2018 Medium

    Linked REV-ERBα degradation to inflammation, showing proinflammatory challenge triggers SUMOylation/ubiquitination-driven loss, and to glucocorticoid signaling via physical GR interaction and chromatin co-binding that times hepatic GC sensitivity.

    Evidence PTM and protein-stability assays, Co-IP, GR/REVERBα ChIP-seq, conditional KO metabolic phenotyping

    PMID:27686098 PMID:29533925 PMID:30179226

    Open questions at the time
    • Direct SUMO/ubiquitin sites not all mapped
    • Mechanism of GR-HSP90 competition partially unresolved
  12. 2017 High

    Established a non-transcriptional genome-protective role: NR1D1 binds PARP1, inhibits PARylation, is recruited to damage sites, and blocks repair-factor (SIRT6/pNBS1/BRCA1) recruitment, inhibiting both NHEJ and HR.

    Evidence DSB reporter assays, domain-deletion mutants, Co-IP, ChIP at lesions, PARP1 activity assays

    PMID:28249904 PMID:28599788

    Open questions at the time
    • Physiological/circadian regulation of DNA-repair role unclear
    • Interplay with transcriptional functions not resolved
  13. 2020 High

    Challenged the dominant hepatic tethering/lipogenesis model, showing antibody-independent hepatocyte ChIP-seq detects binding only at RORE/RevDR2 motifs and that hepatocyte-specific deletion causes only modest, circadian-restricted dysregulation under basal conditions.

    Evidence Antibody-independent ChIP-seq, hepatocyte-specific KO, RNA-seq under basal and challenge states

    PMID:32989157

    Open questions at the time
    • Reconciliation with prior tethering data unresolved
    • Condition-dependence of metabolic role needs broader testing
  14. 2022 High

    Demonstrated state-dependent and tissue-specific metabolic roles, with adipocyte NR1D1 controlling diet-induced obesity and a WAT cistrome revealed only under metabolic challenge, alongside direct repression of mitochondrial/metabolic targets (ACO2) in vascular smooth muscle.

    Evidence Adipocyte- and VSMC-specific KO, ChIP-seq/ChIP, HFD and AAA disease models, metabolite rescue

    PMID:34350828 PMID:35880522

    Open questions at the time
    • Signals that unmask the obese-state cistrome unknown
    • Generality across other metabolic tissues unresolved
  15. 2022 High

    Uncovered cytoplasmic and tissue-specific effector roles: a platelet oligophrenin-1/RhoA/ERM activation pathway and direct repression of myoregulin to maintain skeletal-muscle SR calcium homeostasis.

    Evidence Platelet- and muscle-specific KO, mass spectrometry, Co-IP, ChIP, SR calcium and aggregation assays, dystrophic mouse model

    PMID:35267019 PMID:35917173

    Open questions at the time
    • Mechanism linking REV-ERBα to oligophrenin-1 at molecular level partial
    • Whether platelet role is transcription-independent unresolved
  16. 2023 Medium

    Connected REV-ERBα to lipid-droplet and innate-immune signaling in disease contexts, including sex-dependent microglial lipid-droplet accumulation impairing tau phagocytosis and modulation of cGAS-STING/type I IFN responses in tumors.

    Evidence Cell-type-specific KO, lipid-droplet imaging, tauopathy models, cGAS-STING assays, MMTV-PyMT tumor model, pharmacological SR9009

    PMID:36813093 PMID:37395684 PMID:37626048

    Open questions at the time
    • Molecular basis of sex-dependence unknown
    • Context-dependent pro- vs anti-tumor effects not reconciled

Open questions

Synthesis pass · forward-looking unresolved questions
  • How REV-ERBα's distinct transcriptional, chromatin-looping, DNA-repair, and cytoplasmic effector activities are coordinated, and how its degradation circuits are integrated to set output in each cell type and metabolic state, remains unresolved.
  • No unified model linking nuclear and cytoplasmic functions
  • Structural basis of tethering versus direct binding not defined
  • Reconciliation of conflicting hepatic metabolic models incomplete

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 7 GO:0003677 DNA binding 5 GO:0098772 molecular function regulator activity 3 GO:0008289 lipid binding 1
Localization
GO:0005634 nucleus 3 GO:0000228 nuclear chromosome 2
Pathway
R-HSA-1430728 Metabolism 5 R-HSA-9909396 Circadian clock 5 R-HSA-168256 Immune System 4 R-HSA-74160 Gene expression (Transcription) 4 R-HSA-73894 DNA Repair 2 R-HSA-4839726 Chromatin organization 1
Partners
HDAC3HNF6NCOR1NR1H2NR3C1OPHN1PARP1
Complex memberships
NCoR-HDAC3 corepressor complex

Evidence

Reading pass · 53 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1990 Human Rev-ErbAα (NR1D1) is derived from opposite-strand transcription of the c-erbAα genomic locus and does not bind thyroid hormone, despite 99% identity to the rat homolog in the DNA-binding and putative ligand-binding domains. cDNA cloning, Northern analysis, ligand-binding assay DNA and cell biology High 1971514
1999 Rev-ErbAα binds the HD-PPRE (but not the AOx-PPRE) in vitro and antagonizes PPARα/RXRα-dependent transactivation from an HD-PPRE reporter, identifying the enoyl-CoA hydratase/hydroxyacyl-CoA dehydrogenase (HD) gene as a direct Rev-ErbAα target and revealing cross-talk between Rev-ErbAα and PPARα signaling pathways at a specific response element. In vitro binding analysis, transient transfection reporter assay The Journal of biological chemistry Medium 10428876
2000 Glucocorticoids repress Rev-erbα expression in rat liver and primary hepatocytes at the transcriptional level via the glucocorticoid receptor; the effect is blocked by the GR antagonist RU486 and by actinomycin D, and transient transfection demonstrates GR represses the Rev-erbα promoter directly. In vivo dexamethasone treatment, primary hepatocyte culture, GR antagonist (RU486), actinomycin D, cycloheximide, transient transfection promoter assay Endocrinology High 11014236
2004 Rev-erbAα protein influences myosin heavy chain (MyHC) isoform expression in slow-twitch skeletal muscle; Rev-erbAα knock-out mice show a significantly higher proportion of β/slow (type I) MyHC isoform in the soleus, establishing a role in muscle fiber-type specification. Rev-erbAα knockout mouse model, MyHC isoform analysis, immunohistochemistry American journal of physiology. Regulatory, integrative and comparative physiology Medium 15374821
2008 Heme binds directly to the ligand-binding domain of REV-ERBα and REV-ERBβ and regulates their ability to recruit NCoR (nuclear receptor corepressor) to target gene promoters, establishing heme as an endogenous ligand that controls REV-ERBα transcriptional repressor activity. Ligand-binding assay (direct binding to LBD), co-repressor recruitment assay Molecular endocrinology (Baltimore, Md.) High 18218725
2010 REV-ERBα (NR1D1) is a heme receptor that promotes transcriptional repression by recruiting the NCoR-HDAC3 corepressor complex, and directly represses BMAL1 expression to function as a critical negative limb of the core circadian clock. Review synthesizing ligand-binding, co-repressor recruitment, and gene expression studies Nuclear receptor signaling High 20414452
2011 NR1D1 (Rev-erbα) co-regulates transcriptional networks with NR2E3 in retinal photoreceptors; NR1D1 protein is co-expressed with NR2E3 in rods and cones, and knockdown of Nr1d1 in the developing retina causes pan-retinal spotting and reduced retinal function by electroretinogram. Knock-down in developing retina (morpholino/siRNA), electroretinogram, immunostaining, co-expression analysis PloS one Medium 21408158
2011 Rev-erbα down-regulation by siRNA in pancreatic islet cells impairs glucose-induced insulin secretion, decreases lipogenic gene expression, and inhibits β-cell proliferation; leptin increases Rev-erbα expression via a MAPK pathway. siRNA knockdown, bromodeoxyuridine incorporation, RIA insulin secretion, RT-PCR, in vivo leptin treatment Endocrinology Medium 22166979
2012 REV-ERBα and REV-ERBβ share >50% of genomic binding sites in mouse liver and extensively overlap with BMAL1 cistromes; double knockout mice exhibit profoundly disrupted circadian behaviour and deregulated lipid metabolism, establishing both REV-ERBs as integral components of the principal circadian feedback loop. ChIP-seq (cistromes), double-knockout mouse model, wheel-running behaviour, lipid metabolic profiling Nature High 22460952
2012 Dual depletion of Rev-erbα and Rev-erbβ in mouse embryonic fibroblasts renders them arrhythmic; in liver, both Rev-erbs are recruited to a remarkably similar set of genomic binding sites enriched near metabolic genes, and their combined loss causes marked hepatic steatosis and synergistic derepression of clock and metabolic genes. Double-knockout MEFs (circadian assay), liver-specific depletion, ChIP-seq, gene expression profiling, histological lipid analysis Genes & development High 22474260
2013 ApoA4 binds NR1D1 (identified by bacterial two-hybrid screening; confirmed by co-immunoprecipitation, in situ proximity ligation, and immunofluorescence co-localization), recruits NR1D1 to the Glc-6-Pase promoter, and thereby suppresses hepatic gluconeogenesis; NR1D1 knockdown abolishes ApoA4-mediated repression of PEPCK and Glc-6-Pase. Bacterial two-hybrid library screen, co-immunoprecipitation, in situ proximity ligation assay, immunofluorescence, ChIP, luciferase reporter, siRNA knockdown The Journal of biological chemistry High 24311788
2014 REV-ERBα directly represses Fabp7 transcription in the brain; loss of Rev-erbα leads to Fabp7 overexpression, increased hippocampal neuronal proliferation with loss of its diurnal pattern, and altered memory/mood-related behaviour. Rev-erbα knockout mice, gene expression profiling, BrdU proliferation assay, behavioural testing, in vitro cell assays PloS one Medium 24932636
2014 NR1D1 overexpression in the rd7 mouse (Nr2e3-null) rescues retinal degeneration by re-regulating key genes within the Nr2e3-directed transcriptional network, demonstrating NR1D1 functions as a modifier of Nr2e3-associated retinal disease. In vivo AAV-mediated Nr1d1 delivery, clinical/histological/ERG/molecular outcome measures in rd7 mice PloS one Medium 24498227
2015 REV-ERBα controls the molecular clock by directly competing with ROR transcription factors at cognate DNA sites (universal clock mechanism), whereas it regulates metabolic genes primarily by recruiting HDAC3 co-repressor to sites where it is tethered by cell type-specific (lineage-determining) transcription factors — a tissue-specific epigenomic mechanism. ChIP-seq, genome-wide binding analysis, active-site/domain mutagenesis, HDAC3 co-repressor recruitment assays, liver-specific TF tethering analysis Science (New York, N.Y.) High 26044300
2015 Siah2 E3 ubiquitin ligase mediates circadian degradation of Rev-ErbAα; Siah2 overexpression destabilizes Rev-ErbAα/β, siRNA depletion of Siah2 stabilizes endogenous Rev-ErbAα and delays its circadian degradation, and lengthens circadian period. Functional E3 ligase screen (cell-based), siRNA depletion, overexpression, circadian period measurement Proceedings of the National Academy of Sciences of the United States of America Medium 26392558
2016 CDK1 phosphorylates REV-ERBα, which is necessary for recognition and ubiquitination by the F-box protein FBXW7, leading to REV-ERBα degradation; targeted hepatic disruption of FBXW7 alters circadian gene expression and perturbs lipid/glucose levels, defining a CDK1-FBXW7 pathway that controls circadian amplitude. Co-immunoprecipitation, phosphorylation assays, ubiquitination assay, hepatic FBXW7 knockout mice, circadian gene expression, metabolic profiling Cell High 27238018
2016 HNF6 recruits Rev-erbα to shared hepatic lipid metabolism gene promoters; deletion of HNF6 in adult liver causes loss of Rev-erbα binding at these sites and derepresses lipogenic genes, establishing that HNF6 tethers Rev-erbα to regulate hepatic lipid homeostasis. Liver-specific HNF6 knockout, ChIP-seq, gene expression profiling Genes & development High 27445394
2016 Rev-erbα directly represses Fabp7 and βKlotho (Klb) in white adipose tissue, establishing βKlotho as a tissue-specific Rev-erbα target that modulates FGF21 signaling specifically in adipose (but not liver); Rev-erbα ablation markedly enhances FGF21 effects in WAT. Rev-erbα KO mice, ChIP-seq, gene expression, FGF21 treatment of adipose tissue, cistromic analysis The Journal of biological chemistry Medium 27002153
2016 Nr1d1/Rev-erbα in zebrafish directly regulates autophagy genes through binding to their promoters (ChIP assay) and also modulates c/ebpβ transcription; nr1d1 mutant zebrafish show significantly upregulated autophagy-lysosome genes, establishing a direct circadian clock–autophagy regulatory axis. Luciferase reporter, ChIP assay, TALEN-generated nr1d1 mutant zebrafish, transcriptome analysis Autophagy Medium 27171500
2016 REV-ERBα influences the stability and nuclear localization of the glucocorticoid receptor (GR) by competing for binding to HSP90α/HSP90β chaperone (REV-ERBα binds the C-terminal portion, GR binds the N-terminal portion), thereby affecting expression of GR target genes including IκBα and Adh1. Co-immunoprecipitation (REV-ERBα and GR with HSP90α/β), GR nuclear localization assay, GR target gene expression Journal of cell science Medium 27686098
2017 NR1D1 inhibits both non-homologous end joining and homologous recombination DNA double-strand break repair; PARP1-mediated PARylation of NR1D1 drives its recruitment to DNA damage lesions, and NR1D1 then inhibits recruitment of SIRT6, pNBS1, and BRCA1 to damage sites. Deletion of the NR1D1 ligand-binding domain (which interacts with PARP1) suppresses this recruitment. γH2AX foci assay, NHEJ/HR reporter assays, PARP1 inhibitor, domain deletion mutants, co-immunoprecipitation, ChIP at damage sites Cancer research High 28249904
2017 NR1D1 interacts with PARP1 and inhibits its catalytic (PARylation) activity, thereby enhancing accumulation of ROS-induced DNA damage and increasing breast cancer cell sensitivity to oxidative stress. Co-immunoprecipitation, PARP1 activity assay, DNA damage accumulation assay Molecular and cellular endocrinology Medium 28599788
2017 REV-ERBα directly represses LRH-1 transcription (shown by luciferase reporter, EMSA, and ChIP), and conditional hepatic deletion of Lrh-1 abrogates Rev-erbα regulation of Cyp7a1 and cholesterol metabolism, establishing REV-ERBα→LRH-1→CYP7A1 as the pathway by which Rev-erbα controls bile acid synthesis. Luciferase reporter, EMSA, ChIP, conditional liver Lrh-1 knockout, cholesterol/bile acid measurements Drug metabolism and disposition High 29237721
2017 Rev-erbα overexpression attenuates atrophy-related gene (atrogene) expression and increases fiber size in skeletal muscle; Rev-erbα deficiency causes increased atrogene expression and reduced muscle mass/fiber size; pharmacological Rev-erbα activation blocks dexamethasone-induced muscle atrophy. Gain- and loss-of-function in vivo and in vitro, muscle histology, gene expression, dexamethasone atrophy model Scientific reports Medium 29085009
2017 REV-ERBα binds near driver transcription factor binding sites across the cardiac genome; pharmacological REV-ERBα activation selectively suppresses aberrant pathological gene expression and prevents cardiomyocyte hypertrophy in vitro and in vivo in mouse heart failure models. ChIP-seq, cardiomyocyte hypertrophy assay, in vivo cardiac hypertrophy and heart failure models, gene expression profiling JCI insight Medium 28878135
2018 REV-ERBα opposes functional chromatin loop formation between enhancers and circadian gene promoters by recruiting the NCoR-HDAC3 co-repressor complex, causing histone deacetylation and eviction of elongation factor BRD4 and looping factor MED1, thereby controlling circadian gene transcription through rhythmic chromatin remodeling. Hi-C/chromatin interaction analysis, ChIP-seq, HDAC3/NCoR co-immunoprecipitation, BRD4/MED1 eviction assays Science (New York, N.Y.) High 29439026
2018 REV-ERBα directly represses Nlrp3 transcription by binding to the NLRP3 promoter, and also indirectly represses NLRP3 via repression of p65 (NF-κB); Rev-erbα ablation activates the NLRP3 inflammasome and exacerbates experimental colitis; protective effects of SR9009 are lost in Nlrp3-/- and Rev-erbα-/- mice. ChIP assay, luciferase reporter, Rev-erbα KO and Nlrp3 KO mice, DSS colitis model, cell-based inflammasome assays Nature communications High 30315268
2018 REVERBα physically interacts with the glucocorticoid receptor (GR) and co-binds with liver-specific HNF4A/HNF6 on chromatin; REVERBα promotes efficient GR recruitment to chromatin during the day by maintaining histone acetylation, directing temporal segregation of GC-regulated carbohydrate and lipid metabolism; deletion of Reverba inverts circadian hepatic GC sensitivity. Co-immunoprecipitation, ChIP-seq (GR + REVERBα co-binding), conditional Reverba KO, histone acetylation assays, glucocorticoid metabolic phenotyping The Journal of clinical investigation High 30179226
2018 Inflammatory challenges cause rapid degradation of REV-ERBα protein driven by SUMOylation and ubiquitination; a selective inverse agonist protects REV-ERBα from this degradation, revealing how proinflammatory cytokines trigger REV-ERBα instability to elaborate an inflammatory response. Protein stability assays, SUMOylation/ubiquitination assays, selective antagonist pharmacology, inflammatory cytokine treatment The Journal of clinical investigation Medium 29533925
2018 REV-ERBα competes with RORγt for shared RORE DNA consensus sequences in Th17 cells, repressing RORγt-dependent genes including Il17a and Il17f; REV-ERBα deletion enhances TH17-mediated inflammation and exacerbates EAE and colitis. RORE binding competition assay, REV-ERBα KO mice, EAE and colitis models, cytokine expression, REV-ERB synthetic ligand treatment Cell reports High 30590045
2019 Rev-erbα chromatin immunoprecipitation in primary microglia shows direct interaction with promoter regions of several NF-κB-related genes; Rev-erbα deletion causes spontaneous microglial activation, increased NF-κB signaling, and enhanced neuroinflammatory responses in vivo. ChIP in primary microglia, Rev-erbα KO mice, NF-κB activation assay, inflammatory transcript profiling, LPS neuroinflammation model Proceedings of the National Academy of Sciences of the United States of America Medium 30792350
2019 REV-ERBα inhibits BMAL1 and over-expression or agonist activation of REV-ERBα perturbs lipid signaling pathways used by HCV; genetic knockout of Bmal1 and REV-ERBα activation (by agonist) both inhibit HCV and related flavivirus (dengue, Zika) replication via lipid signaling pathway perturbation. Genetic knockout (Bmal1 KO), REV-ERB agonist treatment, HCV/dengue/Zika replication assays, lipid signaling pathway analysis Nature communications Medium 30670689
2019 REV-ERBα binds RORE elements in Th17 cells and inhibits expression of RORγt-dependent genes Il17a and Il17f; pharmacological REV-ERB agonism delays EAE onset and reduces severity. RORE ChIP/binding assay, Rev-erbα KO, EAE model, cytokine expression, synthetic ligand treatment Proceedings of the National Academy of Sciences of the United States of America Medium 31455731
2019 STRA8 binds the Nr1d1 promoter and directly represses Nr1d1 transcription during spermatogenesis; Nr1d1 upregulation in Stra8-deficient testes drives autophagy through NR1D1 binding to the Ulk1 promoter; genetic deletion or pharmacologic inhibition of Nr1d1 partially rescues meiotic initiation defects in Stra8-deficient mice. ChIP (STRA8 on Nr1d1 promoter; NR1D1 on Ulk1 promoter), Nr1d1 KO, SR8278 pharmacological inhibition, Stra8 KO rescue experiments PLoS genetics High 31059511
2019 Rev-erbα directly represses Pck1 (PEPCK1) transcription through direct binding to a RevRE site at −325 to −320 bp in the Pck1 promoter, as shown by luciferase reporter, EMSA, and ChIP; SR9009 reduces fasting plasma glucose and Pck1 expression in normal and diabetic mice. Luciferase reporter, EMSA, ChIP, Rev-erbα agonist (SR9009) in vivo treatment, glucose tolerance test Pharmacological research High 30639375
2019 Rev-erbα directly represses Ugt2b36 transcription by binding to −30 to −18 bp of its promoter (luciferase, EMSA, ChIP); Rev-erbα KO mice lose Ugt2b rhythmicity in liver, and glucuronidation of morphine is dosing-time dependent consistent with Rev-erbα rhythmic control of Ugt2b enzymes. Luciferase reporter, EMSA, ChIP, Rev-erbα KO mice, morphine glucuronidation kinetics, circadian expression profiling Biochemical pharmacology High 30639455
2019 Rev-erbα exerts cell-autonomous inhibitory effects on myogenic precursor cell proliferation and differentiation, and directly controls the Wnt signaling cascade and proliferative pathway transcriptionally; Rev-erbα loss-of-function augments satellite cell expansion and regeneration after muscle injury. Rev-erbα KO, primary myoblast assays, pharmacological activation/inhibition, muscle injury regeneration model, gene expression Scientific reports Medium 30872796
2020 REV-ERBα deletion causes increased complement gene expression (C4b, C3) in hippocampal neurons and astrocytes, increased microglial synaptic phagocytosis and synapse loss in CA3, and abolishes diurnal variation in synaptic phagocytosis, establishing BMAL1-REV-ERBα as a regulator of complement and synaptic homeostasis. Rev-erbα KO mice, BMAL1 KO mice, complement gene expression (ChIP/RNA), synapse phagocytosis assay, diurnal profiling eLife Medium 33258449
2020 REV-ERBα directly regulates NRF2 transcription and its downstream antioxidant targets SOD1 and catalase in the retinal pigment epithelium (RPE); REV-ERBα deficiency causes accumulated oxidative stress and AMD-like degeneration, while pharmacological activation protects RPE from oxidative damage. RPE-specific Rev-erbα KO, global KO, ChIP (REV-ERBα on NRF2 promoter), antioxidant enzyme expression, oxidative damage assays, pharmacological agonist Redox biology Medium 35176707
2020 Hepatocyte-specific REVERBα ChIP-seq reveals binding exclusively at RORE/RevDR2 motifs with no evidence for tethering/DNA-binding domain-independent action; hepatocyte-specific Reverbα deletion causes only modest transcriptional dysregulation limited to circadian processes under basal conditions, challenging the view that REVERBα is a dominant driver of basal hepatic lipogenesis. Antibody-independent ChIP-seq, hepatocyte-specific Reverbα KO, RNA-seq, metabolic phenotyping under basal and metabolic challenge conditions Proceedings of the National Academy of Sciences of the United States of America High 32989157
2021 NR1D1 directly represses Atg5 transcription by binding to two RORE sites in the Atg5 promoter (dual-luciferase reporter and EMSA); NR1D1 activation reduces autophagy in granulosa cells and Nr1d1 knockdown increases ATG5 expression, regulating follicular autophagy. Dual-luciferase reporter, EMSA, siRNA knockdown, SR9009 agonist treatment, Bmal1 KO mice (indirect) American journal of physiology. Cell physiology Medium 34936504
2021 NR1D1 directly represses CYP19A1 transcription by binding to RORE on the CYP19A1 promoter in ovarian granulosa cells; NR1D1 activation reduces estradiol production and NR1D1 interference eliminates this repression. Luciferase reporter (RORE binding), NR1D1 activation/interference, estradiol RIA Theriogenology Medium 34933195
2021 NR1D1 upregulates SOCS3 expression to suppress JAK/STAT3 signaling in ovarian cancer cells; SOCS3 silencing abolishes NR1D1's antiproliferative effect, establishing the NR1D1→SOCS3→JAK/STAT3 pathway in cancer cell growth control. NR1D1 overexpression/knockdown, CCK8/flow cytometry proliferation assays, Western blot (JAK/STAT3), siRNA (SOCS3 rescue), xenograft model BMC cancer Medium 34330232
2021 Adipocyte-selective NR1D1 deletion does not alter basal WAT lipogenesis but, under high-fat diet, adipocyte NR1D1 KO mice develop profound obesity without accompanying WAT inflammation and fibrosis; NR1D1 cistrome in WAT shows broad metabolic gene control revealed only under obese conditions, indicating NR1D1 is a state-dependent metabolic regulator in adipocytes. Adipocyte-specific Nr1d1 KO, HFD feeding, WAT cistromic analysis (ChIP-seq), RNA-seq, metabolic/inflammatory phenotyping eLife High 34350828
2022 NR1D1 directly trans-represses ACO2 (aconitase-2) in vascular smooth muscle cells; VSMC-specific Nr1d1 KO inhibits AAA formation and restores mitochondrial function by derepressing ACO2; α-ketoglutarate (downstream of ACO2) supplementation prevents/treats AAA in a NR1D1-dependent manner in VSMCs. VSMC-specific Nr1d1 KO mice, AAA models (AngII and CaPO4), ChIP (NR1D1 on ACO2 promoter), mitochondrial metabolism assays, αKG supplementation rescue Circulation High 35880522
2022 Rev-erbα in platelets potentiates activation via the oligophrenin-1-mediated RhoA/ERM (ezrin/radixin/moesin) pathway; mass spectrometry and co-immunoprecipitation identified oligophrenin-1 as a Rev-erbα interacting partner; platelet-specific Rev-erbα KO mice show impaired agonist-induced aggregation, integrin αIIbβ3 activation, and α-granule release. Platelet-specific Rev-erbα KO, mass spectrometry, co-immunoprecipitation, platelet aggregation/activation assays, thrombosis models European heart journal High 35267019
2022 NR1D1 controls skeletal muscle sarcoplasmic reticulum calcium homeostasis by directly repressing myoregulin (a SERCA inhibitor) through binding to the myoregulin promoter; NR1D1 deficiency impairs SERCA-dependent SR calcium uptake; restoration of myoregulin counteracts NR1D1 overexpression effects; pharmacological NR1D1 activation improves SR calcium homeostasis and muscle function in dystrophic mdx/Utr+/- mice. NR1D1 KO mice, ChIP (NR1D1 on myoregulin promoter), SR calcium uptake assays, myoregulin rescue/KO, pharmacological activation, dystrophic mouse model JCI insight High 35917173
2022 NR1D1 protein is degraded in hepatic stellate cells via m6A methylation-induced mRNA ablation during liver fibrosis; NR1D1 deficiency inhibits DRP1S616 phosphorylation, reducing mitochondrial fission and increasing mtDNA release that activates the cGAS pathway, driving local inflammation and fibrosis; NR1D1 overexpression restores DRP1S616 phosphorylation and inhibits cGAS. NR1D1 KO mice, m6A methylation assay, DRP1 phosphorylation Western blot, mitochondrial fission imaging, cGAS pathway assay, NR1D1 overexpression Pharmacological research Medium 36813093
2023 NR1D1 promotes DNA damage-induced accumulation of cytosolic DNA fragments and activates cGAS-STING signaling, increasing type I IFN production and antitumor CD8+ T cell responses; Nr1d1 deletion in MMTV-PyMT tumor cells suppresses type I IFNs and reduces immune infiltration, promoting tumor growth and lung metastasis. Nr1d1 KO in MMTV-PyMT model, orthotopic allograft, cGAS-STING pathway assays, cytosolic DNA quantification, flow cytometry (CD8+ T, NK cells), SR9009 pharmacological treatment Cancer research Medium 37395684
2023 Microglial REV-ERBα deletion enhances inflammatory signaling, disrupts lipid metabolism, and causes lipid droplet (LD) accumulation specifically in male microglia, impairing microglial tau phagocytosis; LD formation blockade partially rescues phagocytosis; microglial REV-ERBα deletion exacerbates tau aggregation and neuroinflammation in tauopathy models in a sex-dependent manner. Microglial-specific Rev-erbα KO, lipid droplet imaging, tau phagocytosis assay, LD inhibitor rescue, two tauopathy mouse models, sex-stratified analysis Nature communications High 37626048
2023 NR1D1 directly binds IL-1β and NLRP3 promoters (shown by ChIP); NR1D1 activation inhibits NLRP3 inflammasome assembly and IL-1β production in nucleus pulposus cells, and delays intervertebral disc degeneration in vivo. ChIP (NR1D1 on IL-1β and NLRP3 promoters), siRNA knockdown, SR9009 agonist treatment, in vivo disc degeneration model iScience Medium 38689641
2021 Polyamines stimulate REV-ERBα protein synthesis at the translational level through enhancement of ribosomal shunting mediated by the 5'-UTR of Rev-erbα mRNA; polyamine reduction lengthens circadian period and reduces REV-ERBα protein, identifying Rev-erbα as a member of the 'polyamine modulon'. Polyamine-reduced cell lines, 5'-UTR reporter constructs (EGFP fusion), circadian period assay, translation assay International journal of molecular sciences Medium 33525630
2020 REV-ERBα overexpression activates mTORC1 signaling by transcriptionally inhibiting the mTORC1 inhibitor Tsc1, leading to increased BMAL1 phosphorylation; REV-ERBα silencing downregulates mTORC1 signaling, linking REV-ERBα to mTOR-mediated circadian clock regulation. REV-ERBα overexpression/silencing, mTORC1 activity assay (S6K phosphorylation), Tsc1 expression (qPCR), BMAL1 phosphorylation, leucine/rapamycin pharmacology Molecular and cellular endocrinology Medium 33285244

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2012 Regulation of circadian behaviour and metabolism by REV-ERB-α and REV-ERB-β. Nature 878 22460952
2012 Rev-erbα and Rev-erbβ coordinately protect the circadian clock and normal metabolic function. Genes & development 416 22474260
2018 REV-ERBα integrates colon clock with experimental colitis through regulation of NF-κB/NLRP3 axis. Nature communications 283 30315268
2015 GENE REGULATION. Discrete functions of nuclear receptor Rev-erbα couple metabolism to the clock. Science (New York, N.Y.) 274 26044300
2019 Circadian clock protein Rev-erbα regulates neuroinflammation. Proceedings of the National Academy of Sciences of the United States of America 218 30792350
2018 Rev-erbα dynamically modulates chromatin looping to control circadian gene transcription. Science (New York, N.Y.) 164 29439026
2018 Circadian clock component REV-ERBα controls homeostatic regulation of pulmonary inflammation. The Journal of clinical investigation 160 29533925
2000 Circadian and glucocorticoid regulation of Rev-erbalpha expression in liver. Endocrinology 151 11014236
2009 Rev-erb-alpha: an integrator of circadian rhythms and metabolism. Journal of applied physiology (Bethesda, Md. : 1985) 144 19696364
2008 Nuclear hormone receptors for heme: REV-ERBalpha and REV-ERBbeta are ligand-regulated components of the mammalian clock. Molecular endocrinology (Baltimore, Md.) 138 18218725
2014 Nuclear receptor Rev-erbα: up, down, and all around. Trends in endocrinology and metabolism: TEM 133 25066191
2016 Circadian Amplitude Regulation via FBXW7-Targeted REV-ERBα Degradation. Cell 130 27238018
2010 Nuclear receptor Rev-erbalpha: a heme receptor that coordinates circadian rhythm and metabolism. Nuclear receptor signaling 123 20414452
2020 Targeting REV-ERBα for therapeutic purposes: promises and challenges. Theranostics 121 32226546
2020 NR1D1 modulates synovial inflammation and bone destruction in rheumatoid arthritis. Cell death & disease 109 32071294
2018 REV-ERBα Regulates TH17 Cell Development and Autoimmunity. Cell reports 97 30590045
2014 The nuclear receptor REV-ERBα regulates Fabp7 and modulates adult hippocampal neurogenesis. PloS one 92 24932636
2016 The circadian clock regulates autophagy directly through the nuclear hormone receptor Nr1d1/Rev-erbα and indirectly via Cebpb/(C/ebpβ) in zebrafish. Autophagy 88 27171500
2022 Nuclear Receptor NR1D1 Regulates Abdominal Aortic Aneurysm Development by Targeting the Mitochondrial Tricarboxylic Acid Cycle Enzyme Aconitase-2. Circulation 83 35880522
2022 The circadian clock protein Rev-erbα provides neuroprotection and attenuates neuroinflammation against Parkinson's disease via the microglial NLRP3 inflammasome. Journal of neuroinflammation 82 35668454
2019 The circadian clock components BMAL1 and REV-ERBα regulate flavivirus replication. Nature communications 82 30670689
2011 The clock gene Rev-erbα regulates pancreatic β-cell function: modulation by leptin and high-fat diet. Endocrinology 80 22166979
2019 The circadian clock protein REVERBα inhibits pulmonary fibrosis development. Proceedings of the National Academy of Sciences of the United States of America 79 31879343
2019 REV-ERBα and REV-ERBβ function as key factors regulating Mammalian Circadian Output. Scientific reports 78 31308426
2019 The nuclear receptor REV-ERBα modulates Th17 cell-mediated autoimmune disease. Proceedings of the National Academy of Sciences of the United States of America 77 31455731
2016 Dysregulated circadian rhythm pathway in human osteoarthritis: NR1D1 and BMAL1 suppression alters TGF-β signaling in chondrocytes. Osteoarthritis and cartilage 73 27884645
2013 Optimized chemical probes for REV-ERBα. Journal of medicinal chemistry 72 23656296
2023 Microglial REV-ERBα regulates inflammation and lipid droplet formation to drive tauopathy in male mice. Nature communications 70 37626048
2017 REV-ERBα ameliorates heart failure through transcription repression. JCI insight 67 28878135
2010 An RNA interference screen identifies metabolic regulators NR1D1 and PBP as novel survival factors for breast cancer cells with the ERBB2 signature. Cancer research 65 20160030
2022 Circadian nuclear receptor Rev-erbα is expressed by platelets and potentiates platelet activation and thrombus formation. European heart journal 64 35267019
2014 Oxidative stress and inflammation modulate Rev-erbα signaling in the neonatal lung and affect circadian rhythmicity. Antioxidants & redox signaling 64 24252172
2018 REVERBa couples the circadian clock to hepatic glucocorticoid action. The Journal of clinical investigation 63 30179226
2020 REV-ERBα mediates complement expression and diurnal regulation of microglial synaptic phagocytosis. eLife 61 33258449
2011 Nuclear receptor Rev-erb alpha (Nr1d1) functions in concert with Nr2e3 to regulate transcriptional networks in the retina. PloS one 61 21408158
2016 HNF6 and Rev-erbα integrate hepatic lipid metabolism by overlapping and distinct transcriptional mechanisms. Genes & development 58 27445394
2017 REV-ERBα Regulates CYP7A1 Through Repression of Liver Receptor Homolog-1. Drug metabolism and disposition: the biological fate of chemicals 56 29237721
2013 Apolipoprotein A-IV reduces hepatic gluconeogenesis through nuclear receptor NR1D1. The Journal of biological chemistry 53 24311788
2008 Association analysis of nuclear receptor Rev-erb alpha gene (NR1D1) with mood disorders in the Japanese population. Neuroscience research 52 18804497
2021 Molecular clock REV-ERBα regulates cigarette smoke-induced pulmonary inflammation and epithelial-mesenchymal transition. JCI insight 51 34014841
2021 Adipocyte NR1D1 dictates adipose tissue expansion during obesity. eLife 48 34350828
2020 Nuclear receptor REVERBα is a state-dependent regulator of liver energy metabolism. Proceedings of the National Academy of Sciences of the United States of America 48 32989157
2017 Rev-erb-α regulates atrophy-related genes to control skeletal muscle mass. Scientific reports 47 29085009
2017 NR1D1 Recruitment to Sites of DNA Damage Inhibits Repair and Is Associated with Chemosensitivity of Breast Cancer. Cancer research 46 28249904
2016 Altered Sleep Homeostasis in Rev-erbα Knockout Mice. Sleep 45 26564124
2016 REV-ERBα influences the stability and nuclear localization of the glucocorticoid receptor. Journal of cell science 45 27686098
2015 Investigation of associations between NR1D1, RORA and RORB genes and bipolar disorder. PloS one 44 25789810
2009 Nr1d1, an important circadian pathway regulatory gene, is suppressed by cigarette smoke in murine lungs. Integrative cancer therapies 43 19926613
2019 Meiotic gatekeeper STRA8 suppresses autophagy by repressing Nr1d1 expression during spermatogenesis in mice. PLoS genetics 42 31059511
2016 The circadian gene Rev-erbα improves cellular bioenergetics and provides preconditioning for protection against oxidative stress. Free radical biology & medicine 42 26855417
2017 The nuclear receptor and clock gene REV-ERBα regulates cigarette smoke-induced lung inflammation. Biochemical and biophysical research communications 41 28974420
1990 Isolation of a cDNA encoding human Rev-ErbA alpha: transcription from the noncoding DNA strand of a thyroid hormone receptor gene results in a related protein that does not bind thyroid hormone. DNA and cell biology 41 1971514
2023 Circadian clock molecule REV-ERBα regulates lung fibrotic progression through collagen stabilization. Nature communications 40 36894533
2020 Circadian asthma airway responses are gated by REV-ERBα. The European respiratory journal 40 32586876
2023 NR1D1 Stimulates Antitumor Immune Responses in Breast Cancer by Activating cGAS-STING Signaling. Cancer research 39 37395684
2019 The Nuclear Receptor and Clock Repressor Rev-erbα Suppresses Myogenesis. Scientific reports 39 30872796
2014 Modifier genes as therapeutics: the nuclear hormone receptor Rev Erb alpha (Nr1d1) rescues Nr2e3 associated retinal disease. PloS one 39 24498227
2004 Aberrant expression of myosin isoforms in skeletal muscles from mice lacking the rev-erbAalpha orphan receptor gene. American journal of physiology. Regulatory, integrative and comparative physiology 37 15374821
2020 Rev-erbα Negatively Regulates Osteoclast and Osteoblast Differentiation through p38 MAPK Signaling Pathway. Molecules and cells 36 31896234
2023 m6A methylation-induced NR1D1 ablation disrupts the HSC circadian clock and promotes hepatic fibrosis. Pharmacological research 35 36813093
2015 Ubiquitin ligase Siah2 regulates RevErbα degradation and the mammalian circadian clock. Proceedings of the National Academy of Sciences of the United States of America 34 26392558
2021 Circadian clock regulates granulosa cell autophagy through NR1D1-mediated inhibition of ATG5. American journal of physiology. Cell physiology 33 34936504
2016 The Nuclear Receptor Rev-erbα Regulates Adipose Tissue-specific FGF21 Signaling. The Journal of biological chemistry 33 27002153
2007 The orphan nuclear receptor Rev-erbalpha: a transcriptional link between circadian rhythmicity and cardiometabolic disease. Current opinion in lipidology 32 17353661
2023 Targeting NR1D1 in organ injury: challenges and prospects. Military Medical Research 31 38072952
2020 Pharmacological modulation and genetic deletion of REV-ERBα and REV-ERBβ regulates dendritic cell development. Biochemical and biophysical research communications 31 32439175
2020 The Effect of Rev-erbα Agonist SR9011 on the Immune Response and Cell Metabolism of Microglia. Frontiers in immunology 31 33101272
2022 REV-ERBα regulates age-related and oxidative stress-induced degeneration in retinal pigment epithelium via NRF2. Redox biology 30 35176707
2020 Pharmacological activation of REV-ERBα improves nonalcoholic steatohepatitis by regulating intestinal permeability. Metabolism: clinical and experimental 30 33096076
2015 Rev-erbα and the circadian transcriptional regulation of metabolism. Diabetes, obesity & metabolism 29 26332963
2018 The circadian gene Nr1d1 in the mouse nucleus accumbens modulates sociability and anxiety-related behaviour. The European journal of neuroscience 28 30028550
2017 Effect of ApoA4 on SERPINA3 mediated by nuclear receptors NR4A1 and NR1D1 in hepatocytes. Biochemical and biophysical research communications 28 28412351
2016 Rev-Erbα modulates retinal visual processing and behavioral responses to light. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 27 27440795
1999 Orphan nuclear hormone receptor RevErbalpha modulates expression from the promoter of the hydratase-dehydrogenase gene by inhibiting peroxisome proliferator-activated receptor alpha-dependent transactivation. The Journal of biological chemistry 27 10428876
2019 Rev-erbα activation down-regulates hepatic Pck1 enzyme to lower plasma glucose in mice. Pharmacological research 26 30639375
2021 NR1D1 suppressed the growth of ovarian cancer by abrogating the JAK/STAT3 signaling pathway. BMC cancer 24 34330232
2021 NR1D1 targeting CYP19A1 inhibits estrogen synthesis in ovarian granulosa cells. Theriogenology 24 34933195
2021 NR1D1 Deletion Induces Rupture-Prone Vulnerable Plaques by Regulating Macrophage Pyroptosis via the NF-κB/NLRP3 Inflammasome Pathway. Oxidative medicine and cellular longevity 24 34956438
2020 The Core-Clock Gene NR1D1 Impacts Cell Motility In Vitro and Invasiveness in A Zebrafish Xenograft Colon Cancer Model. Cancers 23 32244760
2018 Distinct roles for REV-ERBα and REV-ERBβ in oxidative capacity and mitochondrial biogenesis in skeletal muscle. PloS one 23 29723273
2015 Role of the clock gene Rev-erbα in metabolism and in the endocrine pancreas. Diabetes, obesity & metabolism 22 26332975
2022 BMAL1 regulates Propionibacterium acnes-induced skin inflammation via REV-ERBα in mice. International journal of biological sciences 21 35414779
2022 Regulation of Circadian Genes Nr1d1 and Nr1d2 in Sex-Different Manners during Liver Aging. International journal of molecular sciences 21 36077427
2021 Involvement of REV-ERBα dysregulation and ferroptosis in aristolochic acid I-induced renal injury. Biochemical pharmacology 21 34673015
2011 A role for rev-erbα ligands in regulation of adipogenesis. Current pharmaceutical design 20 21375499
2019 The nuclear receptor Rev-erbα participates in circadian regulation of Ugt2b enzymes in mice. Biochemical pharmacology 19 30639455
2023 Rev-erbα agonists suppresses TGFβ1-induced fibroblast-to-myofibroblast transition and pro-fibrotic phenotype in human lung fibroblasts. Biochemical and biophysical research communications 17 37269594
2022 Inhibition of mPGES-2 ameliorates NASH by activating NR1D1 via heme. Hepatology (Baltimore, Md.) 17 35839302
2019 Rev-Erbα and Photoreceptor Outer Segments modulate the Circadian Clock in Retinal Pigment Epithelial Cells. Scientific reports 17 31409842
2015 Dissecting the Rev-erbα Cistrome and the Mechanisms Controlling Circadian Transcription in Liver. Cold Spring Harbor symposia on quantitative biology 17 26370410
2024 Depletion of ApoA5 aggravates spontaneous and diet-induced nonalcoholic fatty liver disease by reducing hepatic NR1D1 in hamsters. Theranostics 16 38505614
2021 Translational Regulation of Clock Genes BMAL1 and REV-ERBα by Polyamines. International journal of molecular sciences 16 33525630
2023 NR1D1 deficiency in the tumor microenvironment promotes lung tumor development by activating the NLRP3 inflammasome. Cell death discovery 15 37524704
2020 Chronopharmacological targeting of Rev-erbα by puerarin alleviates hyperhomocysteinemia in mice. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 15 32006903
2020 REV-ERBα alters circadian rhythms by modulating mTOR signaling. Molecular and cellular endocrinology 15 33285244
2017 NR1D1 enhances oxidative DNA damage by inhibiting PARP1 activity. Molecular and cellular endocrinology 15 28599788
2006 Functional characterization of an orphan nuclear receptor, Rev-ErbAalpha, in chondrocytes and its potential role in osteoarthritis. Arthritis and rheumatism 15 17075855
2022 The nuclear receptor REV-ERBα is implicated in the alteration of β-cell autophagy and survival under diabetogenic conditions. Cell death & disease 14 35428762
2024 SR9009 attenuates inflammation-related NPMSC pyroptosis and IVDD through NR1D1/NLRP3/IL-1β pathway. iScience 13 38689641
2022 NR1D1 controls skeletal muscle calcium homeostasis through myoregulin repression. JCI insight 13 35917173

Missed literature

Know a paper Affinage missed for NR1D1? Flag it for the maintainers and the community.

No submissions yet.